A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease
Status:
Unknown status
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This study is designed as a prospective cohort study to test the strategy of combining two
biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug,
[123I]β-CIT , in a population of first-degree relatives of PD patients as a tool to establish
an 'at risk' Parkinson disease cohort without motor symptoms of PD. First-degree relatives of
PD will be recruited through PD research sites and national foundations to participate in
this study. In addition, first degree relatives of PD patients will be recruited directly
through advertising.
Phase:
Phase 2
Details
Lead Sponsor:
Institute for Neurodegenerative Disorders
Collaborators:
Molecular NeuroImaging United States Department of Defense